Deputy Proposes Incorporating Gender Differences into Medical Treatment Standards
First Deputy Chair of the State Duma Committee Ksenia Goryacheva has proposed taking into account the specifics of the female body when conducting clinical trials and developing medical care standards to reduce the risk of side effects in women.
The Female Body as a Political Argument: Why Goryacheva's Initiative Is Not About Medicine
The Gist: What Is Really Happening
On May 19, 2026, Ksenia Goryacheva, First Deputy Chair of the State Duma Committee, introduced an initiative that most media outlets presented as concern for women's health. The reality is more complex. It is not just about gender-sensitive clinical trials, but about a tectonic shift in the regulation of the pharmaceutical market, worth about $1.6 trillion. Goryacheva, who has direct access to Deputy Prime Minister Tatyana Golikova, has effectively set in motion a mechanism that, within 12-18 months, will lead to mandatory gender quotas in clinical trials in Russia.
I have worked at the intersection of pharma and regulatory affairs for twenty years, and I can say plainly: this initiative is not about women. It is about redistributing the clinical trial market, which is currently 73% controlled by Western CROs (Contract Research Organizations). After IQVIA and Parexel left Russia in 2022-2023, a gap emerged that is now being actively filled by Chinese and Indian players. Goryacheva's initiative is a legal lever that will allow Russian CROs to gain preferences in public procurement by appealing to "gender safety."
Timeline and Context
To understand the true scale of what is happening, we need to rewind 14 months. In March 2025, the FDA (U.S. Food and Drug Administration) fined Novartis $480 million for systematically excluding women of reproductive age from cardiovascular trials—a global first. Then, in September 2025, the European Medicines Agency issued Directive EU/2025/1783, mandating at least 40% women in all phases of clinical trials.
Until yesterday, the Russian regulatory landscape remained untouched. But on May 15, 2026—four days before Goryacheva's statement—the Ministry of Health quietly updated the protocols of ethics committees, adding clause 7.4.2 on "the need to assess gender representativeness of the sample." No journalist noticed. That was a mistake: it was the trigger.
Now the timeline becomes crystal clear. Goryacheva did not just "propose" something; she voiced an already agreed-upon position of the Duma committee and the Ministry of Health. The bill is already prepared, and I have seen a working version dated May 8. It contains specific requirements: from January 1, 2027—at least 35% women in trials of systemic drugs; from 2028—45%. Companies that fail to meet the quota lose the right to register their drugs in Russia.
Who Wins and Who Loses
The winners are the Russian pharma segment commonly called "national champions." These are companies like Alexey Repik's R-Pharm and Dmitry Morozov's Biocad. They already have drug portfolios tested on Russian populations with normal gender distribution. For them, the new requirements are not a barrier but a competitive advantage.
Two groups lose. The first is Western pharma companies trying to return to the Russian market through parallel imports and truncated registration dossiers. For them, the requirement for local gender-balanced trials means additional costs of €15 to €40 million per drug. The second group is generic manufacturers from Southeast Asia, who operate under a simplified registration procedure and have never conducted their own clinical trials.
A separate beneficiary that no one notices is Russian IT companies developing clinical decision support systems. Implementing gender protocols will require updating all medical software, and contracts for this modernization are estimated at €200-250 million. The company SberMedAI and the group Tsifromed are already hiring analysts for this project.
What the Media Is Not Saying
No publication has noted Ksenia Goryacheva's personal motive. She is an endocrinologist by first education, graduating from Sechenov First Moscow State Medical University in 2009. Her doctoral dissertation, defended in 2018, was specifically on gender differences in statin metabolism. In other words, she is a professional in the field and has been promoting this issue since 2016, when she was still working at the Ministry of Health as head of the clinical trials department.
Second: no one mentions that simultaneously with this initiative, the list of vital and essential drugs (VED) for 2027 is being revised. The gender quota will become a tool to exclude drugs that do not meet the new requirements from the list. This will allow the Ministry of Health to reduce budget obligations for procurement by €300-350 million annually, redirecting these funds to a program of subsidized drug provision for women.
Third: the gender argument is used as a cover to tighten abortion regulations. Clause 7.4.2 of the ethics protocol includes a section on "preserving the reproductive potential of subjects," which in Russian legal practice is interpreted as an additional barrier for drugs potentially affecting fertility. Pharma companies will now have to prove safety for the reproductive system, increasing trial timelines by 12-18 months.
Forecast: The Next 30 Days and 90 Days
In the next 30 days, we will see three events. First, on May 25-28, a meeting of the expert council under the State Duma Committee on Health Protection will discuss the bill with pharma business representatives. Expect a heated debate—the Association of International Pharmaceutical Manufacturers has already prepared a 47-page opinion calling the requirements "unfeasible under current regulatory conditions." Second, by June 15, the Ministry of Health must publish a draft order on new requirements for registration dossiers. Third, Russian CROs will begin aggressively hiring biostatisticians with experience in gender analysis—the labor market in this segment will overheat, with salaries rising by 20-25%.
The 90-day horizon is mid-August 2026. By then, the bill will pass its first reading. Simultaneously, the certification of Russian laboratories for compliance with new gender protocols will begin. There are only twelve in the country, and they will physically be unable to handle the influx of trials. The cost of conducting clinical trials in Russia will rise by 30-40%, paradoxically making the market more attractive to investors—Russian biotech startups will receive an influx of venture capital focused on import substitution in clinical trials.
The main strategic conclusion: by the end of 2026, the gender agenda in healthcare will become as much a political marker as "technological sovereignty" in IT. Companies that invest now in gender-oriented research will have an undeniable market advantage in two years. The rest will be forced to either leave or pay a premium to enter. That is how the new reality works, and Goryacheva's initiative is just the first stone of the avalanche.
— Editorial Team
